Since March, the company has won U.S. authorization for five coronavirus tests, including one that can deliver results within minutes and is used at the White House, shielding it from a slide in demand for its medical devices and helping it beat second-quarter profit estimate. Abbott must be feeling very good about some of the diagnostics tailwinds to sustain into second half of the year to put a floor on earnings per share given the uncertainty around a second wave of infections and Medtech procedure volume trends, said Evercore ISI analyst Vijay Kumar. Peer Quest Diagnostics Inc said …read more
Source:: Yahoo Finance
